• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.

作者信息

Koetsawang S, Ji G, Krishna U, Cuadros A, Dhall G I, Wyss R, Rodriquez la Puenta J, Andrade A T, Khan T, Kononova E S

机构信息

Department of Obstetrics and Gynaecology, Siriraj Hospital, Bangkok, Thailand.

出版信息

Contraception. 1990 Feb;41(2):125-41. doi: 10.1016/0010-7824(90)90142-i.

DOI:10.1016/0010-7824(90)90142-i
PMID:2107055
Abstract

This paper investigates the relationship between expulsions and removals, and demographic characteristics of 1005 women from 19 centres using a vaginal ring releasing 20 micrograms levonorgestrel per 24 hours. Emphasis is placed on discontinuations of method use due to expulsions, on the number and rate of expulsions, and the time at which the first expulsion occurred. The overall life-table discontinuation rate due to expulsion was 7.1% at one year. Life-table discontinuation rates increased with parity and were highest in Asian and lowest in European women. In respect to the number of expulsions experienced by women (expulsions did not necessarily lead to discontinuation), the women of high parity and those from Asia and Europe have the highest rates. The life-table first expulsion rate is 29% at one year. Such rates are highest in Chinese and Asian women. Following a first expulsion, the second expulsion rate is 45% by the end of the subsequent six months. The majority of first expulsions occur at defaecation (134 or 57% of 234 women), urination (12%) and during menstruation (17%). Rings were removed by 121 (12%) women on 201 occasions and for a variety of reasons. The main medical reasons were vaginal discharge and irritation, bleeding pain and dyspareunia. Others removed the ring during defaecation, intercourse or because the ring came out of place. Women also removed rings for curiosity, to show their husbands and to clean.

摘要

相似文献

1
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.
Contraception. 1990 Feb;41(2):125-41. doi: 10.1016/0010-7824(90)90142-i.
2
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.微剂量阴道内左炔诺孕酮避孕:一项多中心临床试验。I. 避孕效果和副作用。世界卫生组织。生育调节长效全身用药特别工作组。
Contraception. 1990 Feb;41(2):105-24. doi: 10.1016/0010-7824(90)90141-h.
3
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.微剂量阴道内左炔诺孕酮避孕:一项多中心临床试验。IV. 出血模式。世界卫生组织。生育调节长效全身用药特别工作组。
Contraception. 1990 Feb;41(2):151-67. doi: 10.1016/0010-7824(90)90144-k.
4
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.微剂量阴道内左炔诺孕酮避孕:一项多中心临床试验。III. 妊娠率与体重之间的关系。世界卫生组织。长效全身生育调节制剂特别工作组
Contraception. 1990 Feb;41(2):143-50. doi: 10.1016/0010-7824(90)90143-j.
5
Clinical performance of a levonorgestrel-releasing intracervical contraceptive device during the first year of use.左炔诺孕酮宫内节育器使用第一年的临床性能
Contraception. 1987 Dec;36(6):659-66. doi: 10.1016/0010-7824(87)90039-4.
6
The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort.低剂量左炔诺孕酮阴道环在英国某队列中用于避孕的有效性和可接受性。
Contraception. 1991 Feb;43(2):129-37. doi: 10.1016/0010-7824(91)90040-m.
7
Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.两种经阴道给药避孕药的疗效和可接受性比较研究:一项国际多中心临床试验。
Clin Pharmacol Ther. 1993 Jan;53(1):65-75. doi: 10.1038/clpt.1993.10.
8
Immediate postpartum intrauterine device and implant program outcomes: a prospective analysis.产后即时宫内节育器和植入物项目结果:一项前瞻性分析。
Am J Obstet Gynecol. 2017 Jul;217(1):51.e1-51.e7. doi: 10.1016/j.ajog.2017.03.015. Epub 2017 Mar 23.
9
Risk factors for and outcomes of ring expulsions with a 1-year contraceptive vaginal system.含铜宫内节育器 1 年系统脱落的危险因素及后果
Am J Obstet Gynecol. 2024 May;230(5):548.e1-548.e8. doi: 10.1016/j.ajog.2024.01.020. Epub 2024 Jan 29.
10
Microdose intrauterine levonorgestrel for contraception. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on Intrauterine Devices for Fertility Regulation.微量宫内左炔诺孕酮避孕。世界卫生组织人类生殖研究、发展与研究培训特别规划:生育调节宫内节育器特别工作组。
Contraception. 1987 Apr;35(4):363-79.

引用本文的文献

1
Preference, adherence, and acceptability of 3 nonmedicated intravaginal rings of differing external diameters: a randomized, crossover trial.三种不同外径的非药物阴道环的偏好、依从性和可接受性:一项随机交叉试验。
Am J Obstet Gynecol. 2025 Sep;233(3):188.e1-188.e10. doi: 10.1016/j.ajog.2025.03.001. Epub 2025 Mar 8.
2
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.一项随机、安慰剂对照的 I 期临床试验,评估了连续或周期性使用 90 天替诺福韦加左炔诺孕酮阴道环的安全性、药代动力学、药效学和可接受性:CONRAD 138 研究。
PLoS One. 2022 Oct 10;17(10):e0275794. doi: 10.1371/journal.pone.0275794. eCollection 2022.
3
Acceptability and Satisfaction of Contraceptive Vaginal Rings in Clinical Studies: A Systematic Review and Narrative Synthesis.临床研究中避孕阴道环的可接受性与满意度:一项系统评价与叙述性综合分析
Front Glob Womens Health. 2021 Dec 14;2:799963. doi: 10.3389/fgwh.2021.799963. eCollection 2021.
4
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.随机、安慰剂对照的 I 期临床试验,评估了替诺福韦和替诺福韦加左炔诺孕酮阴道环在女性中的安全性、药代动力学、药效学和可接受性。
PLoS One. 2018 Jun 28;13(6):e0199778. doi: 10.1371/journal.pone.0199778. eCollection 2018.
5
Sustained Release Drug Delivery Applications of Polyurethanes.聚氨酯的缓释药物递送应用
Pharmaceutics. 2018 May 9;10(2):55. doi: 10.3390/pharmaceutics10020055.
6
Hormonal contraceptives for contraception in overweight or obese women.超重或肥胖女性避孕用激素避孕药
Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4.
7
Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine.工程化一种可降解的聚氨酯阴道环用于持续递送达匹韦林。
Drug Deliv Transl Res. 2011 Jun;1(3):223-37. doi: 10.1007/s13346-011-0027-1.
8
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.作为杀微生物剂和多用途预防技术递送系统的阴道环。
Int J Womens Health. 2013 Oct 21;5:695-708. doi: 10.2147/IJWH.S34030.
9
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.用于黏膜 HIV 预防的 90 天替诺福韦储库阴道环。
Antimicrob Agents Chemother. 2012 Dec;56(12):6272-83. doi: 10.1128/AAC.01431-12. Epub 2012 Sep 24.
10
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.多用途预防技术:预防HIV-1、HSV-2和意外怀孕的生物医学工具。
Infect Dis Obstet Gynecol. 2011;2011:1-10. doi: 10.1155/2011/429403. Epub 2011 Aug 9.